Background: Mantle cell lymphoma (MCL) has the worst prognosis of all B-cell lymphomas and has poor response to conventional therapy. It is characterized by the presence of a chromosomal translocation t(11:14) (q13;q32) which results in deregulated cyclin D 1 expression. Since defects in cell cycle regulation and apoptosis are primary events in MCL, small-molecule inhibitors of cdkscyclins may play an important role in the therapy of this disorder. CYC202 (Seliciclib, R-roscovitine; Cyclacel Ltd., Dundee, UK) is a purine analogue and a selective inhibitor of the cdk2 -cyclin E as well as cdk7 -cyclin H and cdk9 -cyclin T.
Introduction
Mantle cell lymphoma (MCL) accounts for approximately 8% of all non-Hodgkin's lymphomas [1] . Despite being previously considered a low-grade indolent lymphoma, it appears to have the worst characteristics of both low-and high-grade lymphomas, i.e. incurability and rapid growth [2] . The median time to progression and survival are the shortest among all lymphoma subtypes [1] . The initiating events of MCL are thought to be caused by the t(11;14) (q13;q32) chromosomal translocation that places the cyclin D 1 gene under the regulation of the immunoglobulin heavy chain (IgH) gene promoter. Additional molecular abnormalities mainly involving genes that regulate the cell cycle, such as loss of p27 protein expression, are also common. Abnormalities regulating apoptosis pathways, have also been identified, including overexpression of Bcl-2 [3] . Currently, there is no convincing evidence that any conventional chemotherapy regimen is curative [4] . Thus there is a need for new therapeutic modalities that would selectively target those pathways that are deregulated [5] . The karyotypic abnormality and the gene expression profile characteristic of MCL and involving mainly proliferation and cell-cycle-related genes make this disease an attractive candidate for therapeutic agents targeted to the cell cycle and apoptosis.
CYC202 (Seliciclib, R-roscovitine) is a purine analogue that competes with ATP for its binding site on cdks. CYC202 is selective towards cdk2-cyclin E, cdk7 -cyclin H and cdk9-cyclin T1, followed by cdk2-cyclin A and cdk1 -Cyclin B [6 -8] . CYC202 has cytotoxic activity against a range of human cancer cell lines, as well as in tumour xenograft models [7] . Phase I clinical trials with an oral capsule formulation have been completed in patients with solid tumours [9] and phase II studies are ongoing for non-small-cell lung cancer. The aim of this work is to assess antitumour activity of CYC202 in MCL cells in vitro and to characterize the mechanisms of action of CYC202 in this disease.
Materials and methods

Cell lines
Four established human MCL cell lines (NCEB-1, REC, Granta-519 and JeKo-1) were used [10] [11] [12] [13] . NCEB-1, JeKo-1 and REC cell lines were cultured in RPMI-1640 (GIBCO Invitrogen, Basel, Switzerland), while Granta-519 cells were cultured in Dulbecco's modified Eagle's medium (GIBCO Invitrogen). All media were supplemented with fetal calf serum (10%), gentamycin (0.1%) and L-glutamine (1%). Classic and molecular cytogenetic techniques were used to confirm the presence of the rearrangement involving the cyclin D 1 (11q13) and the IgH locus (14q32) in all four cell lines (data not shown).
MTT cytotoxicity assay and cell growth inhibition
Cells were seeded into 96-well plates according to doubling time and incubated overnight at 37 8C. CYC202 (Seliciclib, R-roscovitine; Cyclacel Ltd., Dundee, UK) was dissolved in dimethyl sulphoxide (DMSO) and serially diluted in tissue culture media, added to cells (in triplicate) and incubated for 72 h at 37 8C. Control cells were treated with equal amounts of DMSO. A 5 mg/ml stock solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma, Buchs, Switzerland) was prepared in cell media and filter sterilized. MTT solution was then added at 50 ml per well and incubated in the dark for 4 h at 37 8C. Cells were processed as described previously [14] . Absorbance was read at 540 nm on a Beckman Coulter-AD340 instrument.
For cell growth inhibition, cells were seeded in 24-well culture plates at a density of 3 Â 10 5 cells per well. After 24 h, CYC202 was added at the corresponding IC 50 concentration. Cell number and cell viability were determined daily using a Coulter Counter (Beckman Coulter-Z2) and the trypan blue dye exclusion test.
Cell cycle analysis
Cells were treated with DMSO or CYC202 added at the IC 50 concentrations, harvested, washed once in phosphate-buffered saline (PBS) and then fixed in 70% ethanol at À20 8C for at least 1 h. Cells were stained with propidium iodide (PI 50 g/ml, Sigma) in PBS containing RNase-A (75 kU/ml, Sigma) and analysed for DNA content using a FACScan flow cytometer (Becton Dickinson, USA). The analysis of cell cycle and apoptosis was performed using the ModFit LT (Verity Software House Inc., Topsham, ME, USA).
TUNEL assay
Cells were harvested and fixed in 4% paraformaldeyde for 45 min at room temperature, after exposure to IC 50 concentrations of CYC202 or DMSO for 72 h. After rinsing with PBS, the cells were permeabilized in a solution of 0.1% Triton X-100 and 0.1% sodium citrate for 2 min on ice. Samples were washed with PBS and incubated in the TUNEL reaction mixture (Boehringer Mannheim-Roche) for 1 h at 37 8C in the dark. After a final wash with PBS samples were analysed using a FACScan flow cytometer (Becton Dickinson, USA). The percentage of FITC-positive in the overall cell population was determined using the Cell Quest software package (Becton Dickinson).
Western blotting analysis
Cells were solubilized in lysis buffer [10 mM Tris-HCl pH 7.5, 144 mM NaCl, 0.5% Nonidet P-40, 0.5% sodium dodecyl sulphate (SDS), 0.1% aprotinin, 10 mg/ml leupeptin, 2 mM phenylmethylsulfonyl fluoride] and sonicated for 10 s. The protein content in the different samples was determined using the BCA protein assay (Pierce Chemical Co., Rockford, IL, USA). Lysates (30 mg) were fractionated by SDS-PAGE using 8-15% polyacrylamide gels, based upon the expected molecular weight. The resolved proteins were blotted to a nitrocellulose membrane by semi-dry electric transfer, and the membranes were blocked for 1 h in TBS buffer (20 mM Tris-HCl pH 7.6, 137 mM NaCl) containing 5% blotting-grade non-fat milk. Membranes were incubated with primary antibodies diluted in milk with 0.1% Tween 20 overnight. 
Statistics
Groups of data were compared using a paired two-sample Student's t-test.
Results
The effect of CYC202 on viability and growth Granta-519, NCEB-1, REC and JeKo-1 cells were assayed for cell viability after treatment with increasing concentrations of CYC202 using the MTT assay. The IC 50 dose for each cell lines was determined after incubation with the drug for 72 h. CYC202 caused a dose-dependent decrease in cell viability in the four MCL cell lines ( Figure 1 ). An IC 50 of 25 mM was calculated for Granta-519, REC and JeKo-1, and 50 mM for NCEB-1. The anti-proliferative effect of CYC202 was evaluated by measuring the growth rates of MCL cells seeded at low density and treated with a drug dose corresponding to the IC 50 for each cell line (Figure 2 ). Treatment with CYC202 caused a time-dependent inhibition of cell growth in accordance with the cell viability assay.
CYC202-induced changes in the cell cycle
To determine the effects of CYC202 on the cell cycle profile of MCL, the four cell lines were treated with CYC202 for 24 h and 48 h with the corresponding IC 50 drug concentrations. 
CYC202-induced apoptosis in MCL cells
The cell cycle profiles showed an increase in cells with sub-G 1 DNA content after CYC202 treatment, suggestive of induction of apoptosis. To address this question directly, we measured the induction of apoptosis using more sensitive techniques, the TUNEL assay and western blotting with antibodies specific for the cleaved form of PARP. Figure 4 shows the TUNEL assay results after 72 h of treatment with CYC202; apoptosis was present in all the cell lines, with the highest percentage of apoptotic cells in JeKo-1 cells and the lowest in Granta-519 cells. These data were confirmed by western blotting for the detection of the cleaved form of PARP, which showed an increase of cleaved PARP at 24 h and 48 h in all cell lines ( Figure 5 ). Induction of PARP cleavage was particularly prominent in JeKo-1 cells after 24 h of drug treatment. Growth curves of Granta-519, NCEB-1, REC and JeKo-1 MCL cells continuously exposed to the corresponding IC 50 dose of CYC202. Cells were seeded on day 0 and treated with the drug on day 1. Samples were analysed daily for viability and cell number using trypan blue exclusion and an automated cell counter. The differences between control and CYC202 are all statistically significant from the 72 h time point (P < 0.05).
Expression of cell-cycle-related proteins
Owing to the perturbation of the cell cycle induced by CYC202, we analysed by western blotting the expression of proteins involved in the progression of the cell cycle in cells exposed to IC 50 doses of the drug. First, we analysed the expression of cyclin D 1 that regulates cdk4 activity and controls progression through the G 1 phase. Cyclin D 1 is constitutively expressed in MCL and it is believed to play a continuing role in the growth of MCL cells. Cyclin D 1 protein was down-regulated after treatment with CYC202, most dramatically in the NCEB-1 cells (Figure 6 ). No change was observed in the cdk4 level. CYC202 shows activity against cdk7 -cyclin H in vitro. Therefore we analysed the effect of CYC202 treatment on the expression of cyclin H and cdk7 in the MCL cell lines. In the Granta-519, NCEB-1 and JeKo-1 cell lines, cyclin H was down-regulated after 48 h of exposure to the CYC202 ( Figure 6 ). No change in the levels of cyclin H was seen in REC cells. The expression of cdk7 did not change in any of the cell lines.
To investigate the observed G 2 -M accumulation (Figure 3 ) further, cells were treated with the corresponding IC 50 dose of CYC202 for 48 h and cyclin B 1 protein expression was analysed. Up-regulation of cyclin B 1 levels was detected in Granta-519, NCEB-1 and REC compared with the untreated cells ( Figure 6 ). No change in the expression of cyclin B 1 was detected in JeKo-1 cells, consistent with the reduced G 2 -M accumulation detected by flow cytometry in these cells. 
Expression of apoptosis-related proteins
Flow cytometry, TUNEL assay and PARP cleavage western blotting each demonstrated that CYC202 was able to induce apoptosis in all MCL cells. Thus we examined the expression level of proteins that regulate cell survival and apoptosis in cells treated with the drug. No changes were observed in the expression of the anti-apoptotic proteins Bcl-2 and XIAP (BIRC4) or the pro-apoptotic protein Bax were observed (Figure 7) . The level of the anti-apoptotic protein Mcl-1 was considerably down-regulated by treatment with CYC202 in all four cell lines.
Expression of transcription regulatory proteins
To understand the mechanism of cyclin D 1 and Mcl-1 downregulation we looked at the effects of CYC202 on the levels of total and phosphorylated RNA polymerase II and of the transcription factor E2F-1, which is known to regulate Mcl-1 expression negatively. Both RNA polymerase II and E2F1 can be affected by cdk inhibitors. Phosphorylation of the COOHterminal domain of RNA polymerase II is required for transcription elongation and is regulated by cdk7 -cyclin H and cdk9-cyclin T. The levels of both phosphorylated RNA polymerase II and total RNA polymerase II of the protein were decreased after treatment with CYC202 in all the MCL cells (Figure 8 ). E2F-1 was expressed in all four cell lines (Figure 8 ). Its level was increased in NCEB-1. Downregulation of E2F-1 was observed in Granta, Jeko-1 and REC. 
Discussion
MCL is an incurable disorder with a median overall survival of < 2 years. The main genetic event underlying MCL pathogenesis is the presence of the t(11;14) (q13;q32) chromosomal translocation which causes deregulated expression of cyclin D 1 .
In this study we have characterized the effects of the cdk inhibitor CYC202 in human cell lines derived from MCL patients. CY202 is a synthetic cdk inhibitor with most potent activity against the cdk2-cyclin E, cdk7-cyclin H and cdk9 -cyclin T complexes and with anticancer activity demonstrated in solid and haematological tumours [6 -8, 15, 16] . All the MCL cell lines treated showed sensitivity to the compound at doses that are achievable in patients [9] , and it was able to induce apoptosis and caused a slight accumulation of cells in the G 2 -M phase of the cell cycle. We observed a reduction in Mcl-1 and cyclin D 1 levels after treatment with CYC202 in all four cell lines. Mcl-1 is an anti-apoptotic protein, often overexpressed in MCL [17] . It is known to be down-regulated by cdk inhibitors, such as flavopiridol and roscovitine/CYC202 [15, [18] [19] [20] [21] [22] [23] [24] [25] . Other anti-apoptotic molecules (Bcl-2 and XIAP) were not affected by CYC202 treatment. This corroborates the notion that apoptosis induced by some cdk inhibitors might be mediated mainly by changes in Mcl-1 levels and that this can occur despite high levels of Bcl-2 [18, 23] . However, the exact mechanism of apoptosis is not clear yet. Flavopiridol and Roscovitine induce Mcl-1 down-regulation following decreased transcription [23, 26 -30] . Inhibition of cdk7 and cdk9 would ultimately induce the down-regulation of the transcription. An additional mechanism for Mcl-1 down-regulation could be mediated by up-regulation of E2F-1, which directly represses Mcl-1 expression [25, 31] . In our MCL model, only NCEB-1 showed a moderate increase of E2F-1, whilst all the cell lines had a marked reduction of both total and phosphorylated forms of RNA polymerase II levels. E2F-1 might contribute to the apoptotic effect of the drug but, since MCL cells have constitutively high levels of E2F-1 [32] , they might be less sensitive to E2F-1-mediated apoptosis than other cell types. The down-regulation of RNA polymerase II activity and level with consequent inhibition of transcription elongation seems to be the main mechanism for induction of apoptosis in our MCL model. Indeed, we also observed the down-regulation of cyclin D 1 . Both flavopiridol and CYC202 have been shown to decrease the level of cyclin D 1 in other cell types [23, 26, 29, 33] . However, our data in MCL are very interesting. The cyclin D 1 expression is constitutive in MCL owing to the juxtaposition of the gene to the immunoglobulin heavy-chain genes that are always transcriptionally active in B cells. The ability of CYC202 to down-regulate cyclin D 1 expression in this context is very promising for the treatment of MCL patients with the drug. RNA polymerase II has recently been shown to be constitutively bound to both cyclin D 1 promoter and 3 0 IgH regulatory regions in MCL cells [34] . The ability of CYC202 to down-regulate RNA polymerase II activity might explain its marked effect on growth and viability on MCL cells.
In conclusion, our in vitro data indicate that CYC202 is an active compound in MCL with the potential to improve the outcome of patients with this disease. A phase II study that will test the activity of CYC202 in patients with MCL is currently ongoing.
